

POLICY

Policy for Enrolling Children (including Adolescents) in DAIDS- Funded and/or Sponsored Human
Subject Clinical Research: Protocol Document Requirements

Approval Date: Pending

No.: DRAFT

Appendix 2

Waivers of Parental/Guardian Permission or Child Assent

Conditions under which parental/guardian permission may be waived for U.S. Food and
Drug Administration (FDA)-regulated clinical investigations are found at:

21 CFR 50.23 for life threatening situations *Exception from General Requirements* and 21
CFR 50.24, *Exception from Informed Consent Requirements for Emergency Research*. It is not
expected that DAIDS funded and/or sponsored human subject clinical research will
met either of these two conditions.

Conditions under which parental/guardian permission may be waived for non-FDA
regulated clinical research is found at:

45 CFR 46.116(c)

- 1) The research is to be conducted by or subject to the approval of state or
local government officials and is designed to study, evaluate, or otherwise
examine:

- i) public benefit or service programs;
- ii) procedures for obtaining benefits or services under those programs;
- iii) possible changes in or alternatives to those programs or procedures;
- or
- iv) possible changes in methods or levels of payment for benefits or
services under those programs;

and

- 2) The research could not practicably be carried out without the waiver or
alteration.

Or

45 CFR 46.116(d) and (For studies subject to FDA regulations, FDA does not allow
for waiver of parental/guardian permission)

- 1) The research involves no more than minimal risk to the participants;
- 2) The waiver or alteration will not adversely affect the rights and welfare of
the participants;

DAIDS
Bethesda, MD USA

POLICY

Policy for Enrolling Children (including Adolescents) in DAIDS- Funded and/or Sponsored Human
Subject Clinical Research: Protocol Document Requirements

Approval Date: Pending

No.: DRAFT

- 39 3) The research could not practicably be carried out without the waiver or
40 alteration; and
41 4) Whenever appropriate, the participants will be provided with additional
42 pertinent information after participation.
43

44 **Or**
45

46 45 CFR 46.408(c)

47 In the rare situation in which the Institutional Review Board (IRB)/Research
48 Ethics Committee (REC) determines that a research protocol is designed for
49 conditions or for a subject population for which parental or guardian
50 permission is not a reasonable requirement to protect participants (for
51 example, neglected or abused children), it may waive the consent
52 requirements in Subpart A, provided an appropriate mechanism for
53 protecting the children who will participate in the research must be
54 substituted. Such a waiver must be consistent with Federal, State, or local
55 laws.
56

57 The Protocol Team's choice of an appropriate substitute mechanism (for
58 example, appointing a child advocate or an assent monitor) for protecting
59 children participating in research would depend on the nature and purpose of
60 the activities described in the study, the risk and anticipated benefit to the
61 research participants, and the child's age, maturity, status, and condition, as
62 well as approval by the IRB/REC.
63

64 Conditions under which child assent may be waived but parental/guardian permission
65 may be required unless otherwise waived.
66

67 45 CFR 46.116(c)

- 68 1) The research is to be conducted by or subject to the approval of state or
69 local government officials and is designed to study, evaluate, or otherwise
70 examine:
71
72 (i) public benefit or service programs;
73 (ii) procedures for obtaining benefits or services under those programs;
74 (iii) possible changes in or alternatives to those programs or procedures;
75 or
76 (iv) possible changes in methods or levels of payment for benefits or
77 services under those programs;

DAIDS
Bethesda, MD USA

POLICY

Policy for Enrolling Children (including Adolescents) in DAIDS- Funded and/or Sponsored Human
Subject Clinical Research: Protocol Document Requirements

Approval Date: Pending

No.: DRAFT

78
79 **and**

- 80
81 2) The research could not practicably be carried out without the waiver or
82 alteration.

83
84 **Or**

85
86 45 CFR 46.116(d) and 21 CFR 50.55(d)

- 87 1) The research involves no more than minimal risk to the participants;
88 2) The waiver or alteration will not adversely affect the rights and welfare of
89 the participants;
90 3) The research could not practicably be carried out without the waiver or
91 alteration; and
92 4) Whenever appropriate, the participants will be provided with additional
93 pertinent information after participation.

94
95 **Or**

96
97 45 CFR 46.408(a) and 21 CFR 50.55

- 98 1) If the IRB/REC determines that the capability of some or all of the
99 children is so limited that they cannot reasonably be consulted.

100
101 **Or**

- 102
103 2) The intervention or procedure involved in the research holds out the
104 prospect of direct benefit that is important to the health or well-being of
105 the subjects and is available only in the context of the research.